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Background. It is standard practice for laboratories to assess the cellular quality of expectorated sputum specimens to check that 
they originated from the lower respiratory tract. The presence of low numbers of squamous epithelial cells (SECs) and high numbers 
of polymorphonuclear (PMN) cells are regarded as indicative of a lower respiratory tract specimen. However, these quality ratings 
have never been evaluated for induced sputum specimens from children with suspected pneumonia.
Methods. We evaluated induced sputum Gram stain smears and cultures from hospitalized children aged 1–59 months enrolled 
in a large study of community-acquired pneumonia. We hypothesized that a specimen representative of the lower respiratory tract 
will contain smaller quantities of oropharyngeal flora and be more likely to have a predominance of potential pathogens compared to 
a specimen containing mainly saliva. The prevalence of potential pathogens cultured from induced sputum specimens and quantity 
of oropharyngeal flora were compared for different quantities of SECs and PMNs.
Results. Of 3772 induced sputum specimens, 2608 (69%) had <10 SECs per low-power field (LPF) and 2350 (62%) had >25 
PMNs per LPF, measures traditionally associated with specimens from the lower respiratory tract in adults. Using isolation of low 
quantities of oropharyngeal flora and higher prevalence of potential pathogens as markers of higher quality, <10 SECs per LPF (but 
not >25 PMNs per LPF) was the microscopic variable most associated with high quality of induced sputum.
Conclusions. Quantity of SECs may be a useful quality measure of induced sputum from young children with pneumonia.
Keywords. pneumonia; induced sputum; quality; children.
 
Sputum is the lower respiratory specimen most commonly col-
lected from adults as part of the diagnostic workup for com-
munity-acquired pneumonia. However, sputum collection is 
more problematic in children, who typically have difficulty with 
expectoration [1, 2]. Collection of induced sputum through 
methods such as hypertonic saline nebulization can potentially 
overcome this problem.
Specimen quality has a large impact on the interpretation of 
sputum culture results [3]. Specimens originating from the lower 
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respiratory tract can be contaminated by upper respiratory secre-
tions during the collection process, and some poorly collected 
specimens may be entirely composed of upper respiratory secre-
tions. Either situation can lead to the incorrect conclusion that 
an organism colonizing the upper airways is causing pneumo-
nia. Consequently, it has become standard practice for diagnos-
tic laboratories to assess the quality of an expectorated sputum 
specimen using indicators that suggest it has been obtained from 
the lower respiratory tract. This involves assessing the number of 
squamous epithelial cells (SECs) and polymorphonuclear cells 
(PMNs) in a Gram-stained smear of the specimen [4, 5]. The 
presence of low numbers of SECs and high numbers of PMNs 
per low-power field (LPF) have been traditionally regarded as 
being indicative of a high-quality specimen [6]. Likewise, spu-
tum specimens with relatively low numbers of PMNs and high 
numbers of SECs are likely to represent oropharyngeal contami-
nation and are typically rejected for routine culture. These qual-
ity systems have been developed for expectorated sputum from 
adults, but have never been formally evaluated for induced spu-
tum samples from children with suspected pneumonia.
This is the first of 5 companion papers in this supplement 
on induced sputum analysis from the Pneumonia Etiology 
Research for Child Health (PERCH) study. This article is 
focused on the assessment of whether pediatric induced spu-
tum specimens are representative of the lower respiratory tract 
and does not evaluate the utility of induced sputum for diagnos-
tic testing. A specific objective was to identify a quality measure 
indicating a lower-respiratory tract source that could be applied 
to induced sputum specimens from children with pneumo-
nia. Other articles in the supplement focus on the usefulness 
of induced sputum culture, the added value of testing induced 
sputum by polymerase chain reaction (PCR), safety of induced 
sputum collection, and utility of induced sputum for diagnosing 
tuberculosis [7–9].
METHODS
Participants
Participants were children aged 1–59  months who were hos-
pitalized with World Health Organization (WHO)–defined 
severe or very severe pneumonia as part of the PERCH study, a 
case-control study involving 9 sites in 7 countries from sub-Sa-
haran Africa and South Asia. Details of this study have been 
described elsewhere [10, 11]. As part of a comprehensive evalu-
ation, induced sputum was collected from cases, ideally before 
antibiotics were administered.
Specimen Collection
Induced sputum was obtained at enrollment by study staff fol-
lowing an established methodology [12, 13]. A β-2 agonist was 
given by a metered dose inhaler 5 minutes prior to nebulization 
with sterile hypertonic saline (3%–5% sodium chloride) to min-
imize the risk of bronchospasm. Saline nebulization occurred 
for at least 10 minutes using a jet nebulizer with a facemask and 
mixed oxygen flow at a rate of 5–8 L/minute. Percussion of the 
chest wall was done in children <24 months of age during nebu-
lization, and in older children in the absence of cough. Each 
quadrant of the posterior aspect of the chest was tapped gently 
5–10 times to mobilize lower respiratory secretions and induce a 
cough in the child. A sterile mucus extracting catheter attached 
to a suction device was then inserted through the nose into the 
posterior nasopharynx and sputum was collected into a sterile 
trap. Suction was applied only once the catheter was in place and 
not applied during removal of the catheter to avoid aspirating 
anterior nasal contents. The catheter was flushed with 5 mL ster-
ile normal saline at the end of the procedure, and the specimen 
was immediately sent to the laboratory for processing.
Laboratory Methods
Gram-stained smears were made from the most visually puru-
lent portion of each induced sputum specimen. The quality 
of sputum was assessed by determining the numbers of SECs 
and PMNs within the following categories: <10, 10–25, or >25 
cells per representative (×100) LPF. Microorganisms seen in the 
smear under high power (×1000) were described according to 
classic Gram stain morphotypes.
The most purulent portion of each specimen was inocu-
lated onto sheep or horse blood, chocolate, and MacConkey 
agars, streaked out using a standard 4-quadrant streaking 
method, and incubated at 35°C for 48 hours. Cultures were 
examined at 24 hours and 48 hours, and predominant organ-
isms were identified and quantified according to the furthest 
quadrant with visible colonies (first quadrant, scanty; sec-
ond quadrant, 1+; third quadrant, 2+; fourth quadrant, 3+). 
Background mixed oropharyngeal flora (including viridans 
streptococci, commensal Neisseria, coagulase-negative staph-
ylococci, yeasts [except Cryptococcus], diphtheroids, and 
Capnocytophaga) were quantified as a group but not identi-
fied further.
Medical laboratory scientists processed the specimens at each 
site, and efforts were made to standardize these methods across 
all study sites through uniform standard operating procedures, 
on-site training, and internal and external quality checks [14] 
(including participation in the Royal College of Pathologists of 
Australasia’s Quality Assurance Programme).
Study Definitions
Sputum culture results were interpreted using the following 6 
increasingly more rigorous interpretive criteria for each organ-
ism identified:
1. Organism isolated in any quantity;
2. Organism isolated in any quantity and with compatible Gram 
stain morphotype;
3. Organism isolated as the predominant organism;
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S271/3858216
by London School of Hygiene & Tropical Medicine user
on 29 January 2018
Induced Sputum Quality Assessment • CID 2017:64 (Suppl 3) • S273
4. Organism isolated as the predominant organism and with 
compatible Gram stain morphotype;
5. Organism isolated in quantities of 2+ or 3+;
6. Organism isolated in quantities of 2+ or 3+ and with compat-
ible Gram stain morphotype.
Prior antimicrobial therapy was defined as (1) antibiotic activity 
in serum by bioassay, or (2) documented administration of anti-
biotics before induced sputum sample collection [15].
Chest radiographs from each child were read by a panel of 
radiologists and pediatricians trained in the standardized inter-
pretation of pediatric chest radiographs [16]. Chest radiographs 
were classified as either consolidation, other infiltrate, both 
consolidation and other infiltrate, normal, or uninterpretable.
Statistical Analysis
As there are no suitable gold standards to assess sputum quality, 
we identified variables that were likely markers of sputum qual-
ity. We hypothesized that a specimen representative of the lower 
respiratory tract will contain smaller quantities of oropharyn-
geal flora and larger quantities of potential pathogens compared 
to a poor-quality specimen containing mainly saliva.
The prevalence of potential pathogens cultured from induced 
sputum specimens was compared across the 6 interpretive crite-
ria and for different quantities of SECs and PMNs. The quantity 
of oropharyngeal flora was also compared for different quanti-
ties of SECs and PMNs.
To characterize potential correlates of poorer-quality spec-
imens, we used logistic regression models of clinical charac-
teristics (prior antimicrobial use, radiographic pneumonia, 
and human immunodeficiency virus infection), SEC quantity, 
and PMN quantity as predictors of higher oropharyngeal flora 
quantities. Associations between each clinical characteristic 
and oropharyngeal flora quantity were estimated by odds ratios 
(unadjusted and adjusted for all evaluated characteristics and 
PERCH site). Oropharyngeal flora quantity was evaluated as 
quantity greater or equal to 2+ or 3+ vs lower quantity or not 
present.
Ethical Considerations
The study protocol was approved by the institutional review 
board or ethics committee at each of the 7 institutions and at the 
Johns Hopkins School of Public Health. Parents or guardians of 
participants provided written informed consent.
RESULTS
Induced sputum culture results were available for analysis 
from 3772 of 4232 (89.1%) children enrolled in PERCH; 2695 
(71.4%) had severe pneumonia and 1077 (28.6%) very severe 
pneumonia: 518 from Bangladesh, 596 from The Gambia, 
592 from Kenya, 544 from Mali, 824 from South Africa, 191 
from Thailand, and 507 from Zambia. The median age of the 
children was 8 months (interquartile range, 3–16 months), and 
1579 (41.9%) were female; 2833 (75.1%) had evidence of receipt 
of antimicrobials before collection of induced sputum.
Table  1 shows the characteristics of the induced sputum 
specimens by demographic and clinical variables. There was 
variability in the quality of specimens across study sites, with 
large numbers of SECs reported in a higher proportion of cases 
from South Africa. Detection of 4 major potential pathogens 
(Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Staphylococcus aureus) was greater in speci-
mens from children without evidence of prior antibiotic use. 
Otherwise, there was little variation in sputum characteristics 
for most variables.
Over two-thirds of samples had <10 SECs per LPF and a sim-
ilar proportion had >25 PMNs per LPF (Table 2), quantities tra-
ditionally associated with high-quality sputum samples among 
adult populations. A  similar pattern was observed when the 
analysis was restricted to cases with chest radiographic changes 
(Supplementary Table 1A).
Table  3 shows the distribution of organisms cultured from 
sputum samples using the 6 different interpretive criteria. 
Haemophilus influenzae, S.  pneumoniae, and M.  catarrhalis 
were the predominant organisms isolated. The prevalence of all 
organisms declined with progressively more rigorous interpre-
tive criteria, as expected.
Figure 1 shows the prevalence of the 5 major organism group-
ings with differing culture interpretive criteria and with varying 
quantities of SECs and PMNs. The prevalence of H. influenzae, 
S.  pneumoniae, and M.  catarrhalis decreased with increasing 
numbers of SECs. The same relationship was not observed for 
other gram-negative bacteria or S. aureus, for which there was a 
slight increase in prevalence with increasing numbers of SECs. 
The prevalence of all organisms remained relatively unchanged 
with varying numbers of PMNs. These patterns were simi-
lar when the analysis was restricted to cases with chest radio-
graphic changes (Supplementary Figure 1A). The findings were 
also similar when the analysis was stratified by prior antibiotic 
use, although organism prevalence was lower in cases with prior 
antibiotic use (Supplementary Figure 1B and 1C).
Quantity of oropharyngeal flora was recorded in 3677 (97%) 
sputum samples, of which 661 (18%) reported 3+ and 652 (18%) 
reported no oropharyngeal flora (Table 1). The quantity of oro-
pharyngeal flora increased with the presence of greater num-
bers of SECs, but there was no clear association with numbers 
of PMNs (Figure 2). The findings were similar when restricted 
to radiographic pneumonia cases and when stratified by prior 
antibiotic use (Supplementary Figure 2A–C).
Table 4 shows the analysis of variables associated with high quan-
tities of oropharyngeal flora. Sputum specimens with fewer SECs 
were associated with a lower odds of culturing larger quantities of 
oropharyngeal flora. PMNs >25 per LPF was also associated with 
an increased odds of culturing larger quantities of oropharyngeal 
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flora, but the effect size was smaller and (unlike with SECs) there 
was not an increasing trend across PMN categories.
DISCUSSION
The key finding from this study is that <10 SECs per LPF was the 
best measure of induced sputum quality in young children with 
pneumonia, using high quantity of oropharyngeal flora and low 
prevalence of potential pathogens as markers of poorer quality. 
It was also notable that a large proportion (69.1%) of induced 
sputum samples met this criterion for good quality. If this crite-
rion is an accurate marker of good quality, this finding implies 
that a large proportion of induced sputum specimens in this 
study were actually obtained from the lower respiratory tract.
Criteria used by diagnostic laboratories to identify 
microscopically high-quality sputum specimens from 
adults were derived from expert opinion, supported by 
limited data using surrogate markers of quality such as the 
quantity of oropharyngeal flora [4, 5]. Sputum with <10 
SECs and >25 PMNs per LPF have long been regarded as 
ideal [17], although the requirement for large numbers of 
PMNs has been questioned given that some pneumonias 
are not necessarily associated with production of puru-
lent sputum [18]. Indeed, the sentinel study by Murray 
and Washington indicated that <10 SECs was the key 
quality measure, and that the presence of leukocytes did 
not influence the quality interpretation when substantial 
numbers of SECs were present [5]. Our findings sup-
port the application of <10 SECs as a quality measure for 
induced sputum specimens from children as well. The rea-
son for the association between >25 PMNs and increased 
amounts of oropharyngeal flora is unclear, although the 
effect size was small.
Table 2. Comparison of PMN and SEC Quantity in Induced Sputum Samples From Children Aged 1–59 Months With World Health Organization–Defined 
Severe or Very Severe Pneumonia
No. of SECs per LPF
No. of PMNs per LPF
All>25 10–25 <10
 <10 1553 (41.2) 502 (13.3) 553 (14.7) 2608 (69.1)
 10–25 478 (12.7) 137 (3.6) 125 (3.3) 740 (19.6)
 >25 319 (8.5) 47 (1.2) 58 (1.5) 424 (11.2)
 All 2350 (62.3) 686 (18.2) 736 (19.5) 3772 (100.0)
Data are presented as No. (%). Percentages represent percentage of total specimens among cases in whom induced sputum was collected and had available culture results (N = 3772).
Abbreviations: LPF, low-power field; PMNs, polymorphonuclear cells; SECs, squamous epithelial cells.
Table 3. Prevalence of Bacteria by Sputum Culture Interpretive Criteria in Induced Sputum Samples From Children Aged 1–59 Months With World Health 
Organization–Defined Severe or Very Severe Pneumonia (N = 3772)
Potential Pathogens, No. (%b)
Sputum Culture Interpretive 
Criteriaa Spn Saur Oth Strc Hinf Mcat Entrbd Mgnr Ognre Paere
Organism present in any 
amount
1095 (29.0) 387 (10.3) 35 (0.9) 1429 (37.9) 1025 (27.2) 422 (11.2) 165 (4.4) 119 (3.2) 27 (0.7)
Present in any amount with 
compatible Gram stain 
morphotype
947 (25.1) 179 (4.7) 28 (0.7) 1029 (27.3) 781 (20.7) 185 (4.9) 120 (3.2) 58 (1.5) 19 (0.5)
Present as the predominant 
organism
860 (22.8) 291 (7.7) 27 (0.7) 1138 (30.2) 825 (21.9) 329 (8.7) 95 (2.5) 94 (2.5) 24 (0.6)
Present as the predominant 
organism with compatible 
Gram stain morphotype
744 (19.7) 141 (3.7) 23 (0.6) 794 (21.0) 629 (16.7) 145 (3.8) 68 (1.8) 47 (1.2) 16 (0.4)
Present in quantities ≥2+ 683 (18.1) 182 (4.8) 0 (0.0) 819 (21.7) 639 (16.9) 91 (2.4) 39 (1.0) 21 (0.6) 16 (0.4)
Present in quantities ≥2+ with 
compatible Gram stain 
morphotype
626 (16.6) 92 (2.4)  0 (0.0) 613 (16.3) 535 (14.2) 50 (1.3) 23 (0.6) 13 (0.3) 11 (0.3)
Abbreviations: Entrb, Enterobacteriaceae; Hinf, Haemophilus influenzae; Mcat, Moraxella catarrhalis; Mgnr, mixed gram-negative rods; Ognr, other nonfermentative gram-negative rods; Oth 
Str, other streptococci and enterococci; Paer, Pseudomonas aeruginosa; Saur, Staphylococcus aureus; Spn, Streptococcus pneumoniae.
aSputum culture interpretive criteria are not mutually exclusive; children may appear in multiple criteria.
bAll percentages are based on total number of induced sputum specimens (N = 3772).
cOther streptococci and enterococci includes streptococci (other than S. pneumoniae) and enterococci species.
dEnterobacteriaceae includes Escherichia coli, Enterobacter species, Klebsiella species, Citrobacter species, and Serratia species, excluding mixed gram-negative rods.
eOther nonfermentative gram-negative rods includes Acinetobacter species and Pseudomonas species. Pseudomonas aeruginosa also reported separately.
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Figure 1. A–E, Prevalence of organisms by induced sputum culture interpretive criteriaa and induced sputum quality variables in children aged 1–59 months with World 
Health Organization–defined severe or very severe pneumonia. Sputum interpretive criteria: 1, organism present in any amount; 2, present in any amount with compatible 
Gram stain morphotype; 3, present as the predominant organism; 4, present as the predominant organism with compatible Gram stain morphotype; 5, present in quantities 
≥2+; 6, present in quantities ≥2+ with compatible Gram stain morphotype. aSputum interpretive criteria are not mutually exclusive and children will appear in multiple col-
umns. bOther nonfermentative gram-negative rods include Acinetobacter species and Pseudomonas species. Abbreviations: PMNs, polymorphonuclear cells; SECs, squamous 
epithelial cells.
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A large amount of cellular material was obtained from 
most induced sputum samples in this study. More than 
two-thirds of specimens had <10 SECs per LPF and a sim-
ilar proportion had >25 PMNs per LPF (40% had both <10 
SECs and >25 PMNs per LPF). These findings are similar to 
those from other childhood pneumonia studies that collected 
induced sputa [19, 20], and are similar to that reported for 
expectorated sputum from adults with pneumonia [21, 22]. 
Our initial concern that the use of the saline flush in the 
induced sputum collection process may dilute the specimen 
is likely unwarranted, and probably mitigated by the use of 
the most purulent portion of the specimen for making the 
Gram stain smear.
The study has several limitations. Most importantly, we 
lacked a gold standard for good-quality sputum obtained 
from the lower respiratory tract and, instead, relied on sur-
rogate markers such as quantity of background oropharyn-
geal flora. While specimens from the oropharynx are more 
likely to contain large amounts of oropharyngeal flora, true 
lower respiratory specimens will also contain normal com-
mensals from the upper airways through contamination in 
the collection process. The exact relationship between quan-
tities of oropharyngeal flora in upper and lower airways is 
unknown. Second, as expected, we found evidence that anti-
biotic use before specimen collection affects culture findings. 
We accounted for the influence of antibiotics in the analy-
ses, although our imperfect definition of prior antibiotic use 
may have failed to identify cases who had received antibiotics 
[15]. Third, despite efforts to standardize methods across sites 
through training, uniform standard operating procedures, 
and internal and external quality checks, there may still be 
variations in the reporting of sputum cultures and Gram stain 
Figure  2. A–C, Quantity of oropharyngeal flora in induced sputum in children 
aged 1–59 months with World Health Organization–defined severe or very severe 
pneumonia by induced sputum quality variables (N = 3772). Abbreviations: PMNs, 
polymorphonuclear cells; SECs, squamous epithelial cells.
Table  4. Associations of Clinical and Induced Sputum Characteristics 
With 2+/3+ Oropharyngeal Flora in Children Aged 1–59 Months With World 
Health Organization–Defined Severe or Very Severe Pneumonia
2+/3+ OROF
Induced Sputum  
Characteristic
Unadjusted
OR (95% CI)
Multivariable 
Modela
AOR (95% CI)
SECs per LPF
 >25 (reference) 1.00 1.00
 10–25 0.57 (.40–.65) 0.62 (.46–.84)
 <10 0.23 (.19–.29) 0.31 (.23–.41)
PMNs per LPF
 <10 (reference) 1.00 1.00
 10–25 1.05 (.84–1.31) 1.04 (.78–1.38)
 >25 1.60 (1.34–1.91) 1.52 (1.21–1.92)
Prior antibiotic useb 0.58 (.50–.68) 0.72 (.57–.93)
CXR positivec 0.94 (.79–1.13) 0.97 (.82–1.15)
HIV positive 1.19 (.89–1.58) 1.51 (1.02–2.23)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CXR, chest radiograph; 
HIV, human immunodeficiency virus; LPF, low-power field; OR, odds ratio; OROF, oropha-
ryngeal flora; PMNs, polymorphonuclear cells; SECs, squamous epithelial cells.
aAdjusted for all other characteristics included in the model and Pneumonia Etiology 
Research for Child Health (PERCH) site.
bPrior antibiotic use defined as serum bioassay positive, antibiotics received at referral hos-
pital, or administered before induced sputum specimen collection.
cCXR positive defined as any abnormal CXR result (consolidation and/or other infiltrate).
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smears between scientists and between sites. There was vari-
ability in findings between sites (Table 1), and it is uncertain 
the degree to which this reflects true differences in the patient 
populations and whether there is a contribution from inter-
observer variability.
Despite these limitations, the results of this study indicate that 
good-quality sputum specimens can be collected from children 
with pneumonia through saline nebulization induction, and 
that analysis should be restricted to specimens with <10 SECs 
per LPF on Gram stain smear. Although our analysis relied on 
culture results, this restriction identifies characteristics of spu-
tum specimens most likely to be derived from the lower air-
ways and, therefore, the same criterion could also apply to other 
testing methods such as PCR. Subsequent analyses will further 
explore the utility of induced sputum in diagnosing pneumonia 
etiology [9, 23].
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